Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL22123861 | 0.84 | KDM4E (0.33) | CYP3A4ALDH1A1 | |
| SCHEMBL16636894 | 0.81 | TSHR (0.37) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL17649942 | 0.77 | TSHR (0.40) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL18797486 | 0.75 | TP53 (0.32) | TP53 | |
| SCHEMBL29539928 | 0.75 | TP53 (0.32) | TP53 | |
| SCHEMBL3818037 | 0.75 | TSHR (0.39) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL17276042 | 0.75 | TSHR (0.39) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL10990892 | 0.75 | TSHR (0.39) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL5730841 | 0.75 | ALDH1A1 (0.39) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL23336763 | 0.73 | PNMT (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114040914-B | Quinazolinone derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240173310-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| US-20240174633-A1 | CRYSTALLINE FORMS OF (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUORO-METHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4304714-A1 | CRYSTALLINE FORMS OF (4S)-2 4-CHLORO-4-ETHYL-7 3-FLUORO-3 5-METHOXY-3 2,5-DIOXO-1 4-(TRIFLUOROMETHYL)-3 2H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-5 DIBENZENAHEPTAPHANE-7 4-CARBOXAMIDE | Bayer Aktiengesellschaft (DE) | 2024-01-17 | — | — | EP | disclosed |
| EP-4304561-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5- DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)- DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | Bayer Aktiengesellschaft (DE) | 2024-01-17 | — | — | EP | disclosed |
| CN-117337170-A | Comprises (4S) -2 4 -chloro-4-ethyl-7 3 -fluoro-3 5 -methoxy-3 2 5-dioxo-1 4 - (trifluoromethyl) -3 2 H-6-aza-3 (4, 1) -pyridine-1 (1) - [1,2,3]Triazole-2 (1, 2), 7 (1) -diphenyl heptatomato-7 4 Pharmaceutical dosage form of formamide | 拜耳公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117015535-A | (4S)-2 4 -chloro-4-ethyl-7 3 -fluoro-3 5 -methoxy-3 2 5-dioxo-1 4 - (trifluoromethyl) -3 2 H-6-aza-3 (4, 1) -pyridine-1 (1) - [1,2,3]Triazole-2 (1, 2), 7 (1) -5-diphenylheptane-7 4 Crystalline forms of formamide | 拜耳公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-112430234-B | Novel KRAS G12C protein inhibitor and preparation method and application thereof | 信达生物制药(苏州)有限公司 | 2023-04-28 | — | — | CN | disclosed |
| WO-2022189279-A1 | CRYSTALLINE FORMS OF (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-5 DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022189280-A1 | SOLVATES OF (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUORO-METHYL)-32 H-6- AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-15 | — | — | WO | disclosed |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-11-29 | — | — | US | disclosed |
| US-10081617-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-25 | — | — | US | disclosed |
| EP-3368036-A1 | FACTOR XIA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3283464-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017074832-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2016168098-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168098-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079743-A1 | FACTOR XIa INHIBITORS | F11, F2, TFPI | TSHR 3525/4885CYP3A4 1646/4885TP53 4599/4885 |
| US-20240174633-A1 | CRYSTALLINE FORMS OF (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUORO-METHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | CYP4F2, CYP4F8, CYP4F12 | TSHR 1087/4885CYP3A4 21/4885TP53 2549/4885 |
| US-20240173310-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | CYP4F8, CYP4F2, CYP2F1 | TSHR 2381/4885CYP3A4 13/4885TP53 4656/4885 |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | F11, SERPINC1, TFPI | TSHR 3448/4885CYP3A4 1711/4885TP53 4565/4885 |
| US-10081617-B2 | Factor XIa inhibitors | F11, F2, TFPI | TSHR 3525/4885CYP3A4 1646/4885TP53 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.